Key Insights:
A laboratory may offer the required test, but can the result reach the treating team in time? The whitepaper covers:
- How testing access, assay coverage and turnaround times vary across regions.
- How costs, reimbursement, sample availability and laboratory workflows can delay testing or results.
- The role of next-generation sequencing (NGS) as studies require more detailed molecular information.
- Five questions sponsors should ask about testing readiness before finalizing recruitment plans.

Executive Summary:
For patients with advanced non-small cell lung cancer (NSCLC), biomarker results can help guide treatment decisions and identify clinical trial opportunities. When results arrive after treatment has started, some of those opportunities may be missed.
Biomarker testing is widely recommended in advanced NSCLC, but what is tested, who can access testing and how quickly results arrive vary across countries and sites. For sponsors developing biomarker-directed therapies, these differences affect whether eligible patients can be identified within a study’s screening window.
This whitepaper looks at testing practices across the US, Europe, China, Asia-Pacific and Latin America. It outlines what sponsors need to know about local testing pathways to make informed country and site decisions and build realistic recruitment plans.
Explore early-phase clinical development considerations for B-cell depletion in autoimmune disease, including the choice between healthy volunteers and patients, in vivo CAR-T, T-cell engagers, basket studies, and Australia’s role in trial delivery.
Download Novotech’s whitepaper on B-cell depletion strategies and early-phase trial design.





